Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow
Article first published online: 1 MAR 2007
Copyright © 2007 AlphaMed Press
Volume 25, Issue 6, pages 1384–1392, June 2007
How to Cite
Baksh, D., Yao, R. and Tuan, R. S. (2007), Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow. STEM CELLS, 25: 1384–1392. doi: 10.1634/stemcells.2006-0709
- Issue published online: 2 JAN 2009
- Article first published online: 1 MAR 2007
- Manuscript Accepted: 13 FEB 2007
- Manuscript Received: 13 NOV 2006
- Perivascular cells;
- Bone marrow stromal cells;
Human umbilical cord perivascular cells (HUCPVCs) have been shown to have a high proliferative potential and the capacity to differentiate into an osteogenic phenotype. HUCPVCs have thus been considered a possible extra-embryonic mesenchymal stem cell (MSC) source for cell-based therapies. To assess this potential, we compared HUCPVCs to the “gold standard” bone marrow mesenchymal stromal cells (BMSCs) with respect to their proliferation, differentiation, and transfection capacities. HUCPVCs showed a higher proliferative potential than BMSCs and were capable of osteogenic, chondrogenic, and adipogenic differentiation. Interestingly, osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs. Additionally, HUCPVCs expressed higher levels of CD146, a putative MSC marker, relative to BMSCs. HUCPVCs showed comparable transfection efficiency as BMSCs using a nucleofection method but were more amenable to transfection with liposomal methods (FuGENE). Gene array analysis showed that HUCPVCs also expressed Wnt signaling pathway genes that have been implicated in the regulation of MSCs. The similar characteristics between HUCPVCs and MSCs support the applicability of HUCPVCs for cell-based therapies.
Disclosure of potential conflicts of interest is found at the end of this article.